LONDON --(BUSINESS WIRE)--Sep. 13, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present a summary of implantable neuromodulation technology for patients with heart failure during the 23rd Annual Scientific Meeting of the...Read More

Study to evaluate VNS Therapy for Treatment-Resistant Depression in accordance with agency’s National Coverage Determination as part of its Coverage with Evidence Development Program LONDON --(BUSINESS WIRE)--Sep. 5, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and...Read More

LONDON --(BUSINESS WIRE)--Aug. 30, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present two abstracts further establishing the viability of implantable neuromodulation technology to treat patients with heart failure during...Read More

LONDON --(BUSINESS WIRE)--Jul. 31, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2019 . For the second quarter of 2019, worldwide sales from continuing operations were $277.2 million , a decrease...Read More

CE Marked Bi-Flow is the only cannula designed to prevent leg ischemia during cardiac procedures requiring femoral artery cannulation LONDON --(BUSINESS WIRE)--Jul. 16, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today launched its innovative arterial femoral...Read More

The versatile and compact system offers the power and simplicity to support more patients in more places LONDON --(BUSINESS WIRE)--Jul. 15, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has received 510(k) clearance from the U.S....Read More

Revolutionary therapy system has treated more than 120,000 patients worldwide LONDON --(BUSINESS WIRE)--Jul. 11, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, is celebrating the 25th anniversary of its Vagus Nerve Stimulation Therapy ® (VNS Therapy) System....Read More

LONDON --(BUSINESS WIRE)--Jun. 19, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Stacy Enxing Seng , a Venture Partner with Lightstone Ventures and former executive at several healthcare and medical technology companies, was elected by the...Read More

LONDON --(BUSINESS WIRE)--Jun. 17, 2019-- LivaNova PLC  (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second quarter 2019 results on  Wednesday, July 31, 2019 at  1 p.m. London time ( 8 a.m. Eastern Daylight Time )....Read More

LONDON --(BUSINESS WIRE)--May 23, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer, and Thad Huston , Chief Financial Officer, will present at the Jefferies Healthcare Conference on Tuesday, June 4 in New York...Read More

LONDON --(BUSINESS WIRE)--May 16, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer, and Thad Huston , Chief Financial Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 in New...Read More

Key findings from study at Leuven University Hospital show no explants due to structural valve deterioration in 11 years of Perceval use LONDON --(BUSINESS WIRE)--May 3, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that new clinical data for its...Read More

LONDON --(BUSINESS WIRE)--May 1, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2019 . For the first quarter of 2019, worldwide sales from continuing operations were $250.8 million , an increase...Read More

LONDON --(BUSINESS WIRE)--Apr. 5, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced preliminary unaudited revenue results for the quarter ended March 31, 2019 . Preliminary First Quarter 2019 Results The Company expects worldwide sales from continuing...Read More

LONDON --(BUSINESS WIRE)--Apr. 1, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston , Chief Financial Officer of LivaNova , will present at the Needham Healthcare Conference on Tuesday, April 9 in New York at 2:10 p.m....Read More

LONDON --(BUSINESS WIRE)--Mar. 29, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced an agreement to settle approximately 75 percent of the previously disclosed litigation in the U.S. related to the Company’s 3T Heater-Cooler device....Read More

LONDON --(BUSINESS WIRE)--Mar. 18, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Trui Hebbelinck has been appointed Chief Human Resources Officer for the Company. Hebbelinck will lead global human resources, serve on the Executive Leadership Team...Read More

LONDON --(BUSINESS WIRE)--Mar. 15, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology...Read More

LONDON --(BUSINESS WIRE)--Feb. 27, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2018 . For the fourth quarter of 2018, worldwide sales were $297.0 million , an increase of 6.7...Read More

New details provide insights on the suitability of the sutureless aortic valve for future transcatheter solutions LONDON --(BUSINESS WIRE)--Feb. 25, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve...Read More

LONDON --(BUSINESS WIRE)--Feb. 21, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare granted national reimbursement for the Company’s Perceval ® sutureless aortic heart valve to treat aortic valve...Read More

Company plans to submit clinical study protocol for CMS consideration LONDON --(BUSINESS WIRE)--Feb. 15, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today recognized that the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its National Coverage...Read More

LONDON --(BUSINESS WIRE)--Jan. 28, 2019-- LivaNova PLC  (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth quarter and full-year 2018 results on  Wednesday, Feb. 27, 2019 at  1 p.m. London time ( 8 a.m. Eastern Standard Time )....Read More

Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement LONDON --(BUSINESS WIRE)--Jan. 17, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the publication of three separate studies...Read More